Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer

Ying Z. Mazzu(Memorial Sloan Kettering Cancer Center), Philip W. Kantoff(Convergent Science (United States)), Gwo‐Shu Mary Lee(Dana-Farber Cancer Institute), Gouri J. Nanjangud(Memorial Sloan Kettering Cancer Center), HuiYong Zhao(Memorial Sloan Kettering Cancer Center), Travis Gerke(Moffitt Cancer Center), Richard P. Koche(Massachusetts General Hospital), Subhiksha Nandakumar(Memorial Sloan Kettering Cancer Center), Lina Jehane(Memorial Sloan Kettering Cancer Center), Sai Harisha Rajanala(Memorial Sloan Kettering Cancer Center), Yu-Rou Liao(Memorial Sloan Kettering Cancer Center), Yu Chen(Guangdong Academy of Medical Sciences), Anuradha Gopalan(Memorial Sloan Kettering Cancer Center), Ruifang Li(Memorial Sloan Kettering Cancer Center), Goutam Chakraborty(National Centre for Cell Science)
Oncogene
November 20, 2021
10.1038/s41388-021-02118-4
Cited by 18

Related Papers

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2010|5.5k
Genome-wide maps of chromatin state in pluripotent and lineage-committed cells
|Nature|2007|4.2k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
The Molecular Taxonomy of Primary Prostate Cancer
|Cell|2015|3.3k
Gene expression correlates of clinical prostate cancer behavior
|Cancer Cell|2002|2.5k